The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
DARPins: A new generation of protein therapeutics
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
Janeway, C. A., & Medzhitov, R. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.083001.084359 · Cited by 8,394
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161 · cited 1×
“15 Leader, B. et al. (2008) Protein therapeutics: a summary and pharmacological”
BackgroundEngineered antibody fragments and the rise of single domains
Holliger, P., & Hudson, P. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1142 · Cited by 1,931
Pardridge, W. M. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.013 · Cited by 1,191
Arming antibodies: prospects and challenges for immunoconjugates
Wu, A. M., & Senter, P. D. (2005) · Nature Biotechnology · doi:10.1038/nbt1141 · Cited by 1,052
Pegylation: A Novel Process for Modifying Pharmacokinetics
Harris, J. M., Martin, N. E., & Modi, M. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140070-00005 · Cited by 913
Antibody targeted drugs as cancer therapeutics
Schrama, D., Reisfeld, R. A., & Becker, J. C. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1957 · Cited by 768
Somatic diversification of variable lymphocyte receptors in the agnathan sea lamprey
Pancer, Z., Amemiya, C. T., Ehrhardt, G. R. A., Ceitlin, J., Larry Gartland, G., & Cooper, M. D. (2004) · Nature · doi:10.1038/nature02740 · Cited by 677
Engineering novel binding proteins from nonimmunoglobulin domains
Binz, H. K., Amstutz, P., & Plückthun, A. (2005) · Nature Biotechnology · doi:10.1038/nbt1127 · Cited by 676
Self-citationHigh-affinity binders selected from designed ankyrin repeat protein libraries
Binz, H. K., Amstutz, P., Kohl, A., Stumpp, M. T., Briand, C., Forrer, P., Grütter, M. G., & Plückthun, A. (2004) · Nature Biotechnology · doi:10.1038/nbt962 · Cited by 656
Self-citationBinz, H. K., Stumpp, M. T., Forrer, P., Amstutz, P., & Plückthun, A. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00896-9 · Cited by 589
Self-citationPEGylated antibodies and antibody fragments for improved therapy: a review
Chapman, A. P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00026-1 · Cited by 556
Elimination mechanisms of therapeutic monoclonal antibodies
Tabrizi, M. A., Tseng, C.-M. L., & Roskos, L. K. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03638-x · Cited by 478
Drug Export Pathway of Multidrug Exporter AcrB Revealed by DARPin Inhibitors
Sennhauser, G., Amstutz, P., Briand, C., Storchenegger, O., & Grütter, M. G. (2006) · PLoS Biology · doi:10.1371/journal.pbio.0050007 · Cited by 334
Self-citationRibosome display: selecting and evolving proteins in vitro that specifically bind to a target
Zahnd, C., Amstutz, P., & Plückthun, A. (2007) · Nature Methods · doi:10.1038/nmeth1003 · Cited by 308
Self-citationAlternative non-antibody scaffolds for molecular recognition
Skerra, A. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.04.010 · Cited by 300
Koren, E., Zuckerman, L., & Mire-Sluis, A. (2002) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201023378175 · Cited by 267
BiTEs: bispecific antibody constructs with unique anti-tumor activity
Wolf, E., Hofmeister, R., Kufer, P., Schlereth, B., & Baeuerle, P. A. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03554-3 · Cited by 260
A Designed Ankyrin Repeat Protein Evolved to Picomolar Affinity to Her2
Zahnd, C., Wyler, E., Schwenk, J. M., Steiner, D., Lawrence, M. C., McKern, N. M., Pecorari, F., Ward, C. W., Joos, T. O., & Plückthun, A. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.03.028 · Cited by 256
Imaging Tumors with an Albumin-Binding Fab, a Novel Tumor-Targeting Agent
Dennis, M. S., Jin, H., Dugger, D., Yang, R., McFarland, L., Ogasawara, A., Williams, S., Cole, M. J., Ross, S., & Schwall, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2531 · Cited by 251
Fibronectin as target for tumor therapy
Kaspar, M., Zardi, L., & Neri, D. (2006) · International Journal of Cancer · doi:10.1002/ijc.21677 · Cited by 249
Tolmachev, V., Orlova, A., Pehrson, R., Galli, J., Baastrup, B., Andersson, K., Sandström, M., Rosik, D., Carlsson, J., Lundqvist, H., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1630 · Cited by 220
Steiner, D., Forrer, P., Stumpp, M. T., & Plückthun, A. (2006) · Nature Biotechnology · doi:10.1038/nbt1218 · Cited by 213
Self-citationA new generation of protein display scaffolds for molecular recognition
Hosse, R. J., Rothe, A., & Power, B. E. (2006) · Protein Science · doi:10.1110/ps.051817606 · Cited by 211
Rudge, J. S., Holash, J., Hylton, D., Russell, M., Jiang, S., Leidich, R., Papadopoulos, N., Pyles, E. A., Torri, A., Wiegand, S. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708865104 · Cited by 203
Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs
Holt, L. J., Basran, A., Jones, K., Chorlton, J., Jespers, L. S., Brewis, N. D., & Tomlinson, I. M. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzm067 · Cited by 193
Interspecies Scaling of Clearance and Volume of Distribution Data for Five Therapeutic Proteins
Mordenti, J., Chen, S. A., Moore, J. A., Ferraiolo, B. L., & Green, J. D. (1991) · Pharmaceutical Research · doi:10.1023/a:1015836720294 · Cited by 191
In vitro display technologies: novel developments and applications
Amstutz, P., Forrer, P., Zahnd, C., & Plückthun, A. (2001) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(00)00234-2 · Cited by 181
Self-citationFolding and Unfolding Mechanism of Highly Stable Full-Consensus Ankyrin Repeat Proteins
Wetzel, S. K., Settanni, G., Kenig, M., Binz, H. K., & Plückthun, A. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.11.046 · Cited by 178
Self-citationA novel strategy to design binding molecules harnessing the modular nature of repeat proteins
Forrer, P., Stumpp, M. T., Binz, H. K., & Plückthun, A. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00177-7 · Cited by 174
Self-citationMonoclonal antibodies in the clinic
Reichert, J. M. (2001) · Nature Biotechnology · doi:10.1038/nbt0901-819 · Cited by 168
Hermeling, S., Caetano, L. A., Damen, M. J. A., Slijper, M., Schellekens, H., Crommelin, D. J. A., & Jiskoot, W. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-8177-9 · Cited by 144
Schweizer, A., Roschitzki‐Voser, H., Amstutz, P., Briand, C., Gulotti-Georgieva, M., Prenosil, E., Binz, H. K., Capitani, G., Baici, A., Plückthun, A., et al. (2007) · Structure · doi:10.1016/j.str.2007.03.014 · Cited by 133
Self-citationConsensus Design of Repeat Proteins
Forrer, P., Binz, H. K., Stumpp, M. T., & Plückthun, A. (2004) · ChemBioChem · doi:10.1002/cbic.200300762 · Cited by 111
Self-citationAllosteric Inhibition of Aminoglycoside Phosphotransferase by a Designed Ankyrin Repeat Protein
Kohl, A., Amstutz, P., Parizek, P., Binz, H. K., Briand, C., Capitani, G., Forrer, P., Plückthun, A., & Grütter, M. G. (2005) · Structure · doi:10.1016/j.str.2005.04.020 · Cited by 89
Self-citationRapid selection of specific MAP kinase-binders from designed ankyrin repeat protein libraries
Amstutz, P., Koch, H., Binz, H. K., Deuber, S. A., & Plückthun, A. (2006) · Protein Engineering Design and Selection · doi:10.1093/protein/gzl004 · Cited by 77
Self-citationStabilizing Ionic Interactions in a Full-consensus Ankyrin Repeat Protein
Merz, T., Wetzel, S. K., Firbank, S. J., Plückthun, A., Grütter, M. G., & Mittl, P. R. E. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.11.047 · Cited by 60
Consensus Design as a Tool for Engineering Repeat Proteins
Kajander, T., Cortajarena, A. L., & Regan, L. (2006) · Humana Press eBooks · doi:10.1385/1-59745-116-9:151 · Cited by 53
Marvin, J. S., & Zhu, Z. (2006) · PubMed · Cited by 25
Designed Ankyrin Repeat Proteins as Anti‐Idiotypic‐Binding Molecules
Vogel, M., Gautschi, E., Baumann, M. J., Amstutz, P., Ruf, C., Kricek, F., & Stadler, B. M. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1398.002 · Cited by 16
Self-citation
Cited by
Srinivasarao, M., & Low, P. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00013 · Cited by 605
De novo design of potent and selective mimics of IL-2 and IL-15
Silva, D.-A., Yu, S., Ulge, U. Y., Spangler, J. B., Jude, K. M., Labão-Almeida, C., Ali, L. R., Quijano-Rubio, A., Ruterbusch, M., Leung, I., et al. (2019) · Nature · doi:10.1038/s41586-018-0830-7 · Cited by 531
Engineered protein scaffolds as next-generation antibody therapeutics
Gebauer, M., & Skerra, A. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.04.627 · Cited by 341
Nonspecific Binding—Fundamental Concepts and Consequences for Biosensing Applications
Frutiger, A., Tanno, A., Hwu, S., Tiefenauer, R. F., Vörös, J., & Nakatsuka, N. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00044 · Cited by 278
Metadata
- Authors
- Stumpp, M. T., Binz, H. K., & Amstutz, P.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2008-08
- Volume
- 13
- Issue
- 15-16
- Pages
- 695-701
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2125130429
- Cited by
- 254
- References
- 42
- FWCI
- 7.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.